Read our latest news, and find more about us and our portfolio companies.
Plexium Inc. announced the appointment of experienced biopharmaceutical leader Percival Barretto-Ko as President and Chief Executive Officer and a member of the Board of Directors
Xilio Therapeutics, Inc. today announced the closing of its previously announced initial public offering of 7,353,000 shares of its common stock at a price to the public of $16.00 per share
Partner Shanghai Miracogen (fully owned by LEPU BIOPHARMA CO., LTD) commences US Phase I/II trial with ADC designed to treat solid tumors MRG004A selected for clinical development based on highly competitive efficacy and tolerability in preclinical studies compared to conventional ADC technology Over 10 ADCs currently being developed by Synaffix licensees
Refreshed brand identity reflects Altoida’s emphasis on data and humanity, and will support the company’s growth as the world leader in Precision Neurology
Theolytics is harnessing viruses to combat cancer: transforming patients’ lives; through world leading science; with a great team.
Proceeds to fund early pipeline of novel switchable bispecific T-cell engagers to treat solid tumor cancers Company's proprietary T-LITE platform based on small molecule-dependent activation of T-cell engagers, enabling potentially safer and more efficacious tumor targeted therapy Seasoned leadership to steer company's growth and pipeline development
Seed round was led by M Ventures and INKEF Capital, and co-led by Taiho Ventures and Bioqube Ventures
FoRx Therapeutics announces the appointment of Tarig Bashir as Chief Executive Officer
STORM Therapeutics today announces the appointment of Professor Tsutomu Suzuki to its Scientific Advisory Board (SAB)
Forendo Pharma today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook
• Deal led by Rock Springs Capital and joined by Bain Capital Life Sciences, Deerfield Management, RA Capital Management and other investors • Proceeds will advance XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4) into the clinic • Two investigational new drug (IND) applications planned in 2021
* Artios Pharma transitions to a clinical-stage precision medicine company * Advances next generation DNA Damage Response (DDR) treatment targeting ATR in patients with advanced or metastatic solid tumors
Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders - Company also announces appointment of biotech veteran Mike Grey as Chairman of the Board